Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
NCT ID: NCT00262899
Last Updated: 2013-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
331 participants
INTERVENTIONAL
2005-08-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized clinical trial is studying how well genetic counseling works compared to usual care in helping patients with newly diagnosed ductal carcinoma in situ, stage I, stage II, or stage IIIA breast cancer make treatment decisions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improving Genetic Counseling for BRCA+ Mothers
NCT04258280
Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer
NCT01386411
Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer
NCT05325151
Development of a Genetic Counseling Patient Preference Intervention for Women at Elevated Risk for Breast Cancer
NCT05158452
Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing
NCT00165152
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Compare the impact of rapid genetic counseling (RGC) vs usual care on the medical decisions of women with newly diagnosed ductal carcinoma in situ or stage I-IIIA breast cancer.
* Compare the impact of these interventions on the quality of life and psychological well being of these patients.
* Determine baseline factors that predict who is most and least likely to benefit from RGC in patients undergoing these interventions.
* Compare the cost per quality adjusted life year saved from a societal perspective in patients undergoing these interventions.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating site. Patients are randomized to 1 of 2 interventional arms.
* Arm I (rapid genetic counseling): Patients undergo a 1½ hour genetic counseling session either in person or by telephone. Patients who undergo telephone counseling receive a booklet of visual aids and educational materials. Patient preferences and values are assessed immediately after counseling. Some patients may undergo BRCA1/2 status determination. Patients undergo follow-up telephone interviews at 1, 6, and 12 months.
* Arm II (usual care): Patients receive a packet of breast cancer treatment educational materials. Patient preferences and values are assessed 2 weeks later. Patients undergo follow-up telephone interviews as in arm I.
In both arms, quality of life is assessed at baseline and at 1, 6, and 12 months.
After completion of the study, patients are followed periodically for 1 year.
PROJECTED ACCRUAL: A total of 360 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rapid genetic counseling
Following randomization, participants will be informed about whether they are assigned to Usual Care (UC) or Rapid Genetic Counseling (RGC). Participants in the UC arm can schedule a genetic counseling appointment at any time during the study if they wish. Participants in the RGC agree to obtain genetic counseling as soon as possible, before they make a definitive surgery decision. RGC can be accomplished by telephone or in-person. The RGC intervention is delivered by highly experienced genetic counselors at each site. This counseling is identical to our standard genetic counseling procedure for newly diagnosed patients. Immediate DNA collection via blood or buccal cell collection is available following counseling. Phone counseling participants will be been mailed a kit for DNA collection or have the option of having the sample collected at at LCCC.
counseling intervention
educational intervention
psychosocial assessment and care
Usual Care
Usual Care (UC) for newly diagnosed breast cancer patients does not typically include a pre-surgical genetic referral. These patients may obtain genetic counseling at their own discretion.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
counseling intervention
educational intervention
psychosocial assessment and care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosed breast cancer, meeting 1 of the following criteria:
* Stage 0 disease (ductal carcinoma in situ only)
* Stage I-IIIA disease
* Must meet 1 of the following criteria:
* Diagnosis before 50 years of age
* Diagnosis after 50 years of age AND has 1 of the following:
* First or second degree relative diagnosed with breast cancer before 50 years of age
* First or second degree relative diagnosed with ovarian cancer at any age
* First or second degree relative diagnosed with male breast cancer at any age
* Must not have initiated definitive treatment for breast cancer
* No bilateral, metastatic, or inflammatory breast cancer
* No prior BRCA1/2 counseling or testing
* No prior diagnosis of metastatic cancer of any type
* Hormone receptor status:
* Not specified
PATIENT CHARACTERISTICS:
Sex
* Female
Menopausal status
* Not specified
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
PRIOR CONCURRENT THERAPY:
Surgery
* No prior bilateral mastectomy for breast cancer
Other
* No concurrent treatment for cancer
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Georgetown University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marc D Schwartz
Professor of Oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc Schwartz, PhD
Role: STUDY_CHAIR
Lombardi Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Chevy Chase, Maryland, United States
Hackensack University Medical Center Cancer Center
Hackensack, New Jersey, United States
Mount Sinai School of Medicine
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schwartz MD, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O'Neill S, Jandorf L, Kelly SP, Heinzmann J, Zidell A, Khoury K. Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients. Breast Cancer Res Treat. 2018 Aug;170(3):517-524. doi: 10.1007/s10549-018-4773-3. Epub 2018 Apr 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GUMC-2004-212
Identifier Type: -
Identifier Source: secondary_id
CDR0000450155
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.